TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06672770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Inspiratory Muscle Training
Description: The functional inspiratory muscle training group will perform basic inspiratory muscle training in the first four weeks of the study and the following exercises with the Powerbreath device in muscle training in the following four weeks:~1. Diaphragmatic breathing exercises~2. Warm-up exercises~3. Trunk strength and lumbopelvic stability exercises~4. Dynamic trunk exercises~5. Postural control exercises~6. Cool-down exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Inspiratory Muscle Training
Description: The basic inspiratory muscle training group will do muscle training with the POWERbreathe device for eight weeks.
Study: NCT05017831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Treatment
Description: Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Treatment
Description: Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition. CRT is a behavioral treatment that presents tasks to participants in a standardized order within each session. Each task has a number of levels. Participants stay at the same task-based level until mastered. They then move up a level on that task. participants can be at different levels on different tasks within each session. After completion of tasks, participants are asked to reflect on their thought processes in solving the tasks. Standard prompts are used to guide the discussion.
Study: NCT06671327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preemptive Dexmedetomidine injection
Description: The DEX group was continuously pumped at 1.5 μg /(kg·h) for 15 minutes before induction, and after induction continue infusion 15min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: The Placebo group was infused with equal amounts of isochronous normal saline.
Study: NCT04773041

Intervention type: PROCEDURE
Intervention: Infinitome
Description: All patients will have rs-FMRI images analyzed with the Infinitome cloud-based software processing program.

Intervention type: PROCEDURE
Intervention: Infinitome
Description: All patients will have rs-FMRI images analyzed with the Infinitome cloud-based software processing program.

Intervention type: PROCEDURE
Intervention: Infinitome
Description: All patients will have rs-FMRI images analyzed with the Infinitome cloud-based software processing program.
Study: NCT06113666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)
Description: dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital patient education about insomnia (PE)
Description: Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.
Study: NCT05176847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcasts and tips of the day (within app)
Description: Participants will receive twice weekly podcasts and daily tips of the day, with nutrition and exercise information, audio diary and goal setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Podcasts and tips of the day (within app)
Description: Participants will receive twice weekly podcasts and daily tips of the day, with nutrition and exercise information, audio diary and goal setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mLIFE app (self-regulation features)
Description: Diet (track by in app database), physical activity (tracked with FitBit and synced with mLIFE app), and weight (tracked with FitBit scale and synced with mL app) tracking app components. App notifications and reminders and newsfeeds.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mLIFE app (self-regulation features)
Description: Diet (track by in app database), physical activity (tracked with FitBit and synced with mLIFE app), and weight (tracked with FitBit scale and synced with mL app) tracking app components. App notifications and reminders and newsfeeds.
Study: NCT04714060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-621
Description: mAb by SC administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-621
Description: mAb by SC administration
Study: NCT04710823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: A bolus dose of 0.25% bupivacaine (0.3 ml/kg) will be injected slowly over 3-5 minutes. At 30 minutes after injection of the loading dose, the dermatomal loss of sensation to pinprick was tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion will be continued for 4 days.
Study: NCT06385990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTD1
Description: UTD1: 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.
Study: NCT04710823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block
Description: A bolus of 30 ml of 0.25% bupivacaine will be injected slowly over 3-5 minutes between latissmus dorsi muscle and serratus anterior muscle (Figure 15). Then a catheter was inserted through the Tuohy needle and advanced 3cm into the space and secured in place. At 30 minutes after injection of a loading dose, the dermatomal loss of sensation to pinprick will be tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion was continued for 4 days.
Study: NCT04968054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm I (Propofol)
Description: Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm II (Remimazolam)
Description: Remimazolam group started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
Study: NCT06168760

Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric Measurements
Description: Anthropometric measurements of the hand were measured with a digital caliper. Anthropometric measurements were determined as hand length, width and finger lengths, taking into account previous studies. Manual dexterity was evaluated with the 9-Hole Peg Test.
Study: NCT06063707

Intervention type: OTHER
Intervention: Taking peripheral blood
Description: Taking peripheral blood of no more than 3ml

Intervention type: OTHER
Intervention: Taking peripheral blood
Description: Taking peripheral blood of no more than 3ml
Study: NCT04733378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peri-operative neurological monitoring
Description: Pre- and post-operative cerebral MRI, standardized neurological examinations at 4, 12, 24 months and neuropsychological evaluation with a Bayley III test (Bayley Scale of Infant and Toddler Development, Third Edition) at 24 months.
Study: NCT05472454

Intervention type: OTHER
Group type: OTHER
Intervention: Ready-to-eat meals
Description: Participant group to consume ready-to-eat meals in accordance with the DASH diet for a period of 4 weeks.
Study: NCT04689815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Arsenic Trioxide Formulation
Description: Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle). Each cycle of oral-As2O3 plus azacitidine will be given once every 28 days. The total duration of treatment is 12 months (12 cycles). Treatment will be day-care and outpatient based. Reduction in the dosage and duration of oral-As2O3 is required if the subject is experiencing adverse events (AEs). In case of grade 3 or above toxicity, the dosage of oral-As2O3 will be reduced to 5mg per day.
Study: NCT06411353

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI acquisition
Description: Non-contrast enhanced acquisitions will be performed using a whole-body MRI scanner operating at 1.5 Tesla or greater.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: US examination
Description: A complete assessment of the AVF vessels is performed using advanced 3D US procedures.
Study: NCT05042388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA)
Description: Integrates evidenced-based practices to decrease the probability and severity of relapse for those in addiction recovery. MBRP incorporates components from CBT relapse prevention and includes training in meditation practices as a means to foster increased awareness of emotional and cognitive experiences. MBRP also includes training in brief informal meditations aimed at increasing awareness and adaptive response to drug cues and negative affect.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-As-Usual
Description: Standard treatment programming procedures for all individuals residing within the residential treatment program. Includes: supportive group therapy; Narcotics Anonymous/12-Step Programming; music, art, and animal therapy; psycho-education on general issues related to mental health and SUDs; and medication counseling.
Study: NCT05988697

Intervention type: DRUG
Intervention: Combind asprin with Trametinib and Dabrafenib
Description: Treatment drug: Dabrafenib 150 mg BID, Trametinib 2 mg QD, Aspirin 100 mg/tablet, 1 tablet/time, QD
Study: NCT06256120

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Restrictive
Description: 3 mL/kg/hour Ringer Lactate will be given peroperatively to the restrictive group (Group R).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liberal
Description: 7 ml/kg/hour Ringer Lactate will be given peroperatively to the liberal group (Group L).
Study: NCT05176847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mLIFE app (social support features)
Description: The gamified mLIFE app contains several components to help facilitate social gaming and support. This includes a newsfeed, to view the progress of other users, the ability to send others encouragement (likes/thumbs-up) for achieving goals, user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members.~For the experimental group, the app also includes features that facilitate healthy competition among participants through receipt of points for provision of social support and tracking health behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard mLIFE app (social support features)
Description: The standard mLIFE app has the ability to send others encouragement (likes/thumbs-up) for achieving goals and a user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members.
Study: NCT06471647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delta-9-tetrahydrocannabinol (THC) (5)
Description: 5 mg of THC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - dextrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delta-9-tetrahydrocannabinol (THC) (10)
Description: 10 mg of THC
Study: NCT05925959

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Weight Management Program
Description: The medical obesity intervention is comprised of monthly visits with an obesity medicine (OM) provider +/- a registered dietitian (in person or virtual). Lifestyle modifications (nutrition, physical activity, stress, sleep), appetite control, and medication side effects will be addressed in all visits. At initial visit, patients will evaluated in person by an OM provider +/- registered dietitian. An individualized intense lifestyle intervention will be implemented with the addition of an anti-obesity medication (phentermine, naltrexone/bupropion, phentermine/topiramate, liraglutide, semaglutide, etc). Medication use will be based on disease risk, patient preference, severity of obesity, contraindications, potential drug interactions and insurance coverage. A diet recommendation will be tailored to the patient's medical and food allergy history. Weight and vital signs will be monitored at each visit. Participants will have a total of 5 follow-up monthly encounters, every 30 +/- 7 days.
Study: NCT04888221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered subcutaneously at a dose of 162mg/0.9mL weekly (each week, on the same day) from week 0 to week 24.~At the first injection (Baseline D0), a therapeutic education is provided for patients/caregivers who can carry out the injections themselves as part of their usual care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously (SC) weekly during 24 weeks
Study: NCT06396156

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior enclavation
Description: Anterior enclavation of iris-claw lens

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior enclavation
Description: Posterior enclavation of iris-claw lens
Study: NCT06029816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib tablets
Description: Neratinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib tablets
Description: Neratinib tablets
Study: NCT03610815

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening, Brief Intervention, Referral to Treatment
Description: Screening, Brief Intervention, Referral to Treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening, Brief Intervention, Referral to Treatment
Description: Screening, Brief Intervention, Referral to Treatment
Study: NCT06548074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: H-PACE Behavioral Intervention
Description: Participate in the H-PACE program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: Wear an accelerometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Parents may participate in an optional virtual peer support group
Study: NCT05568706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will take EDP-938 once daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take matching placebo, once daily for 5 days
Study: NCT04509102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adderall-XR
Description: Subjects randomized to Adderall XR will initiate treatment with 15 mg daily (one 15 mg tablet each morning) for 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar for 21 days.
Study: NCT06561971

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
Study: NCT05851105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: α-globin restored autologous hematopoietic stem cells
Description: α-globin restored autologous hematopoietic stem cells modified with LentiHBA T\>C
Study: NCT05651568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodized resistance training
Description: It consists of patients who will receive periodized resistance training 3 sessions per week for 8 weeks. Resistance training has been performed according to FITT principal and as per ACSM recommendation.~Frequency:~Three days in a week~Intensity:~60% intensity with one repetition maximum and 10% intensity were added each the two weeks.4 sets and 8-12 rep as per ACSM criteria. There will be rest of 60 second after every set and 120 seconds after every exercise.~Type:~8 types of resistance exercises were performed. There were 4 set of each exercise with 8 to 12 repetitions. These exercises are smith press, seated press, squat, lying dumbbell leg curls, leg extension, leg press, standing barbell, lying barbell and sit ups.~Time:~40 minutes per session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: It consists of patients who will receive high intensity interval training 3 sessions per week for 8 weeks for 30 to 35 minutes.~Active phase: Two weekly sessions of four times four minutes at 90-95% of individual heart rate maximum, separated by three minutes of active rest period and one weekly session of ten times one minute with maximal intensity, separated by one minute of active rest. The exercise mode will be treadmill or outdoor walking/running or cycling (self-selected).
Study: NCT05956379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Physical therapists will provide personalized aerobic exercise program prescriptions in the preparatory period based on the results of exercise-related assessments, and the training intensity is based on the results of the maximum exercise test, with moderate intensity for 24 weeks, \>=3 cardio workouts per week. The form of aerobic exercise can be carried out in the form of treadmill walking, walking, jogging, cycling, aerobic dance, ball games, swimming, rope skipping, stepping exercises, etc. When the exercise reaches the target intensity, we will adjust the training intensity process according to personal ability. The physical therapist will again adjust the content of the aerobic exercise program at week 12 based on the reassessment of the exercise capacity.
Study: NCT06029816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib tablets
Description: Neratinib tablets
Study: NCT04518657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention for Physical Activity in MS (BIPAMS)
Description: A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing physical activity in people with MS.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wellness for MS (WellMS)
Description: A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing wellness in people with MS.
Study: NCT05836779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514 injection
Description: CBL-514 will be administered at the raised area of cellulite.
Study: NCT05065775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Single intranasal dexmedetomidine dose of 100 µg. Intranasal dexmedetomidine will be administered shortly after induction of anesthesia using a mucosal atomization devise (LMA MAD Nasal™)
Study: NCT05257551

Intervention type: OTHER
Intervention: Observation
Description: No intervention
Study: NCT05522920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy with and without spinal cord stimulation
Description: Conventional therapy only will be followed with conventional therapy combined with electrical spinal cord stimulation.